Foundation for the National Institutes of Health

US Navy Veterans Mesothelioma Advocate Urges a Navy Veteran Who Served in A Navy Ship's Engine Room and Now Has Mesothelioma to Call Attorney Erik Karst of Karst von Oiste for a Compensation Claim Evaluation-It Might Be Millions

Friday, September 24, 2021 - 1:34pm

A Mesothelioma compensation settlement for a person like this might be in the millions of dollars-because their exposure to asbestos may have been so extreme.

Key Points: 
  • A Mesothelioma compensation settlement for a person like this might be in the millions of dollars-because their exposure to asbestos may have been so extreme.
  • "To get the financial compensation for a Navy Veteran like this who now has mesothelioma we have endorsed, and we highly recommend attorney Erik Karst of the law firm of Karst von Oiste.
  • Aside from being one of the nation's leading mesothelioma attorneys Erik Karst of Karst von Oiste specializes in assisting Navy Veterans with this rare cancer caused by asbestos exposure.
  • It is this information that becomes the foundation for a mesothelioma compensation claim as mesothelioma attorney Erik Karst is always happy to discuss at 800-714-0303."

Greenlight Guru Opens New Global Headquarters in Downtown Indianapolis

Thursday, September 23, 2021 - 2:00pm

INDIANAPOLIS, Sept. 23, 2021 /PRNewswire-PRWeb/ -- Greenlight Guru, pioneer of the only dedicated Medical Device Success Platform (MDSP), will host a grand opening celebration today to its new Indianapolis headquarters.

Key Points: 
  • INDIANAPOLIS, Sept. 23, 2021 /PRNewswire-PRWeb/ -- Greenlight Guru, pioneer of the only dedicated Medical Device Success Platform (MDSP), will host a grand opening celebration today to its new Indianapolis headquarters.
  • Since the beginning of COVID-19, Greenlight Guru has more than doubled its headcount, aiding in the growth and development of the Indianapolis tech community.
  • While the new headquarters is located in Indianapolis, the hybrid work culture has been embraced company-wide.
  • The Indianapolis tech community is invited to attend the grand opening event on Thursday, September 23, 2021today, from 4:30 to 6:30 p.m. at the new Greenlight Guru headquarters, located at 601 S Meridian St. Suite 500, Indianapolis, IN.

DTx Pharma to Present at Upcoming Investor Conferences

Thursday, September 16, 2021 - 12:30pm

Dr. Suckow will present a company overview and host one-on-one meetings at both conferences.

Key Points: 
  • Dr. Suckow will present a company overview and host one-on-one meetings at both conferences.
  • He will also participate in a panel discussion on RNA delivery at the Chardan conference.
  • In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types.
  • To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.

American Skin Association Announces New Board Member Eugene A. Bauer, MD

Wednesday, September 15, 2021 - 4:36pm

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.
  • He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company.
  • "We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors.
  • Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company.

Recent Fluvoxamine COVID benefits discovered using Cytel-designed platform trial

Monday, September 13, 2021 - 7:00am

There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.

Key Points: 
  • There is no other treatment for early COVID that has been shown to prevent the need for hospitalization.
  • Platform trials, such as those used to test fluvoxamine, allow multiple therapies to be tested using a single study design with a shared control arm.
  • Dr. Wathen is well known for his work in platform trials having helped design several platform trials previously and his contributions and help in designing the I-SPY 2 trial, a platform trial that transformed breast cancer research.
  • The TOGETHER TRIAL may also open the door for platform trials to become a much more widespread research study design.

DentalPlans.com Warns About the Association Between Poor Oral Health and Alzheimer’s Disease

Wednesday, September 1, 2021 - 3:04pm

Alzheimers disease is the most common form of dementia, affecting more than six million Americans most of them age 65 or older according to the Alzheimers Association and is the sixth-leading cause of death in the United States.

Key Points: 
  • Alzheimers disease is the most common form of dementia, affecting more than six million Americans most of them age 65 or older according to the Alzheimers Association and is the sixth-leading cause of death in the United States.
  • And, as the National Institute of Health states, living a healthy lifestyle may reduce your risk of being impacted by dementia.
  • The next step for researchers is performing clinical trials to determine whether dental deep cleanings can help prevent Alzheimers disease.
  • This research further demonstrates the association between oral health and overall health that we already know exists.

Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)

Tuesday, August 31, 2021 - 1:00pm

Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.

Key Points: 
  • Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.
  • "I'm hopeful that these resources will help parents and families learn more, feel less alone and raise awareness about the physical and emotional impacts of these rare conditions."
  • "It's great to have additional resources, created by and for the community, to help raise awareness and education about PROS."
  • Located in East Hanover, NJ, Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives.

Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

Monday, August 30, 2021 - 1:30pm

Oak Ridge, TN, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2021.

Key Points: 
  • The Companys increase in revenue of 26.5% in the Companys diagnostic division, represents strong strides in the commercialization of its BVA-100 Blood Volume Analyzer and eight additional accounts.
  • Updates on the initiation of a National Institutes of Health multicenter prospective randomized control trial in heart failure management utilizing Daxors technology were also given.
  • Daxors research trial at the VA Hospital System is in excellent shape, noted Chief Scientific Officer Jonathan Feldschuh.
  • We are excited to update shareholders that this landmark trial has begun and enrollment is on track.

Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant

Tuesday, August 24, 2021 - 3:00pm

Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine.

Key Points: 
  • Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine.
  • This is the first clinical trial of a candidate from the companys adjuvant and vaccine portfolio.
  • These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.
  • About Adjuvance Technologies: Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing.

Study By Providence Researchers On Remdesivir Reinforces Need To Define Optimal Treatment Of Covid-19

Thursday, August 19, 2021 - 4:42pm

The research published in the Clinical Infectious Diseases journal, suggestedRemdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.

Key Points: 
  • The research published in the Clinical Infectious Diseases journal, suggestedRemdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.
  • Remdesivir reduces mortality by 40% in COVID patients who receive treatment while on low flow oxygen.
  • "These findings are significant because they highlight the urgent need to define optimal treatment of COVID-19.
  • It shows that Remdesivir was associated with lower mortality compared to best supportive care for certain patients.